人脱细胞血管与大隐静脉在慢性肢体缺血患者动脉旁路术中的结局比较
本研究比较了6毫米直径人脱细胞血管(HAV)与自体大隐静脉(GSV)在晚期外周动脉疾病(PAD)患者膝下旁路术中的结局。HAV组34例,GSV组88例为多中心历史队列。中位随访12个月时,两组大截肢无生存率和总生存率相当,但HAV组一期、一期辅助和二期通畅率均较低。
要点
- HAV组更常用于再次手术和更严重的肢体缺血患者。
- 中位12个月时,HAV组与GSV组的大截肢无生存率分别为73%和81%,无显著差异(P=0.55)。
- HAV组的一期通畅率(36% vs 50%,P=0.044)、一期辅助通畅率(45% vs 72%,P=0.002)和二期通畅率(64% vs 72%,P=0.003)均低于GSV组。
核心结论
- 在FDA扩大准入计划下植入的HAV更可能用于再次手术和肢体缺血更严重的病例。
- 尽管一期通畅率不高,HAV在无自体静脉选择的复杂队列中表现出韧性,获得了良好的二期通畅率,并在12个月时提供了与GSV相当的大截肢无生存率。
研究设计与样本
- HAV组(第1组)为34例接受6毫米直径HAV旁路术的晚期PAD且无自体静脉条件的患者(2021年3月至2024年2月)。
- GSV组(第2组)为88例接受单段大隐静脉旁路术的多中心历史队列(2017年1月至2022年12月)。
- HAV在FDA签发的扩大准入计划的研究性新药方案下使用。
主要发现
- 两组人口统计学特征相当(平均年龄69±10岁;男性71%)。
- 第1组吸烟率更高(37包年 vs 28包年;P=0.059)、冠心病比例更高(71% vs 43%;P=0.007)、既往冠状动脉旁路移植术比例更高(38% vs 14%;P=0.003)。
- 第1组伤口、缺血和足部感染临床4期患者更多(56% vs 33%;P=0.018),既往同侧下肢血运重建史更多(97% vs 53%;P<0.001)。
- 两组慢性肢体威胁性缺血(Rutherford 4-6级)患者数量相似(88% vs 86%;P=0.693),全球解剖分期系统III期比例相似(91% vs 96%;P=0.346)。
- 第1组85%的旁路术需要使用复合移植物(两条HAV缝合在一起)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Human Acellular Vessel (HAV) is a novel, off-the-shelf biologic conduit being evaluated for arterial reconstructions. Regulatory studies in peripheral arterial disease (PAD) to date have consisted of single-arm cohorts with no comparator groups to contrast performance against established standards. This study aimed to compare outcomes of the HAV with autologous great saphenous vein (GSV) in patients with advanced PAD undergoing infrageniculate bypass. METHODS: Patients with advanced PAD and no autologous conduit who underwent bypass with the 6-mm diameter HAV (Group 1; n = 34) (March 2021-February 2024) were compared with a multicenter historical cohort who had bypass with single-segment GSV (group 2; n = 88) (January 2017-December 2022). The HAV was used under an Investigational New Drug protocol issued by the Food and Drug Administration (FDA) under the agency's Expanded Access Program. RESULTS: Demographics were comparable between groups (mean age 69 ± 10 years; 71% male). Group 1 had higher rates of tobacco use (37 pack-years vs 28 pack-years; P = .059), coronary artery disease (71% vs 43%; P = .007), and prior coronary artery bypass grafting (38% vs 14%; P = .003). Group 1 had more patients classified as wound, ischemia, and foot infection clinical stage 4 (56% vs 33%; P = .018) and with previous index leg revascularizations (97% vs 53%; P < .001). Both groups had a similar number of patients with chronic limb-threatening ischemia (Rutherford class 4-6) (88% vs 86%; P = .693) and Global Anatomic Staging System stage III (91% vs 96%; P = .346). Group 1 required a composite conduit (two HAV sewn together) in 85% of bypasses. The tibial vessels were the target in 79% of group 1 and 100% of group 2 (P < .001). Group 1 had a lower mean operative time (364 minutes vs 464 minutes; P < .001). At a median of 12 months, major amputation-free survival (73% vs 81%; P = .55) and overall survival (84% vs 88%; P = .20) were comparable. Group 1 had lower rates of primary patency (36% vs 50%; P = .044), primary-assisted patency (45% vs 72%; P = .002), and secondary patency (64% vs 72%; P = .003) compared with group 2. CONCLUSIONS: Implanted under Food and Drug Administration Expanded Access provisions, the HAV was more likely to be used in redo operations and cases with more advanced limb ischemia than GSV. Despite modest primary patency, the HAV demonstrated resilience in a complex cohort with no autologous conduit options, achieving good secondary patency and providing major amputation-free survival comparable with GSV at 12 months.
引用
- Cifuentes S, Sen I, DeMartino RR, et al. Comparative outcomes of arterial bypass using the human acellular vessel and great saphenous vein in patients with chronic limb ischemia. J Vasc Surg. 2024. PMID: 38904582. doi:10.1016/j.jvs.2024.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。